![]() |
|
| |||||||||||||||||
G-PROTEIN-COUPLED RECEPTORS: Cheek to cheek
Several key GPCR families contain functional interfaces consisent with dimerization, and a putative receptor-binding site on G proteins is consisent with binding to a GPCR dimer. The pivotal position of G-protein-coupled receptors (GPCRs) in cell-signalling pathways means they are attractive drug targets; indeed, over 50% of current drugs directly affect GPCRs. As early as the mid-1970s, it was proposed that GPCRs might form dimers or oligomers, but it is only recently that the idea has become more generally accepted. Nevertheless, much remains to be elucidated about the functional significance of dimerization; for example, whether it is necessary for receptor activation and how widespread it is among different GPCR families. By analysing the wealth of GPCR and G-protein sequences in combination with structural data, Christopher Reynolds and co-workers have provided evidence that several key GPCR families contain functional interfaces consistent with dimerization, and that a putative receptor-binding site on G proteins is consistent with binding to a GPCR dimer.
Members of the GPCR superfamily all share the same basic architecture — seven transmembrane a-helices, an extracellular amino-terminal segment and an intracellular carboxy-terminal tail. Reynolds and colleagues used the evolutionary trace (ET) method to infer the location of functional sites within different GPCR families. Essentially, this data-mining method identifies amino-acid residues with high levels of conservation. These family-specific 'trace' residues are then mapped on to a representative superfamily structure. Clustering of trace residues indicates sites that are likely to impart functional specificity to family members. The seven families studied include many important drug targets, such as The possibilities raised by GPCR homo- and heterodimerization vastly increase the potential pharmacological diversity of this family, and have important implications for the discovery of new drugs that target these receptors; for example, assays that test potential GPCR modulators could involve multiple receptors. Exploitation of these phenomena could be a very promising route to more selective and efficacious drugs in this key class. Peter Kirkpatrick References
| |||||||||||||||||
![]() | |||||||||||||||||
HOME | SIGNALING UPDATE | MOLECULE PAGES | DATA CENTER | ABOUT US | |||||||||||||||||